IDEAYA Biosciences Inc (NAS:IDYA)
$ 37.71 -0.74 (-1.92%) Market Cap: 2.85 Bil Enterprise Value: 2.16 Bil PE Ratio: 0 PB Ratio: 3.01 GF Score: 37/100

IDEAYA Biosciences Inc at Guggenheim Healthy Altitudes Summit Transcript

Mar 15, 2023 / 01:15PM GMT
Release Date Price: $15.49 (-2.64%)
Charles Zhu
Guggenheim Partners - Analyst

(technical difficulty) and thanks for joining us today. I'm Charles Zhu. I'm one of the senior biotech analysts here at Guggenheim. With me here today is Yujiro Hata, CEO of IDEAYA Biosciences. Thank you for joining us here today as well. Perhaps just to kick us off very quickly, a one-minute overview of your company pipeline and platform.

Yujiro Hata
IDEAYA Biosciences, Inc. - President & CEO

First, Charles, thanks so much to Guggenheim to inviting us again to the event this year. So quickly, the company was founded just over 7.5 years ago with a core focus to build the leading synthetic lethality focused-precision medicine oncology company.

Today, we have three first-in-class clinical programs, darovasertib, which we're targeting to have a discussion with the FDA this month on a potential registration-enabling trial. The second program, which is a MAT2A inhibitor, here, the patient selection biomarker is MTAP deletion, that's believed to represent roughly 15% of all solid tumors. Here, the key focus is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot